Seelos Therapeutics, Inc. SEEL Cash Flow

Seelos therapeutics, inc. (SEEL)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Cash flows from operating activities:
Net loss and comprehensive loss
-20,575	-51,255	-41,816	-39,692	-38,326	-3,475	-4,701	-7,436	-8,413	321	2,468	5,009	3,145	-7,433	-9,466	-13,209	-15,116	-19,023	-33,979	-32,058	-24,936	-21,786	-5,843	-5,715	-11,527	-16,938	-35,230	-34,740	-35,731	-31,771	-16,825	-16,550	-19,418	-18,117	0	0	0
Net income (loss) from discontinued operations
-	-	-	-	-	-	-	-	-	12,070	11,933	12,061	11,694	226	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain (loss) from discontinued operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,068	-5,260	-6,047	-6,772	-6,095	0	0	0	-	-	-	-
Net loss from continuing operations
-	-	-	-	-	-	-	-	-	-11,749	-9,465	-7,052	-8,549	-7,659	0	0	0	-	-	-	-	-	-	-	-	-15,870	-29,970	-28,693	-28,959	-25,676	0	0	0	-	-	-	-
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization
-	-	-	-	-	-	-	-	-	117	-13	38	90	106	293	296	298	300	292	279	224	170	122	76	76	77	-250	48	126	203	602	380	454	602	0	0	0
Stock-based compensation expense
732	459	314	184	63	33	269	597	862	1,138	1,223	1,225	1,676	1,747	1,725	1,690	1,276	1,210	1,187	1,309	1,529	1,731	1,826	1,790	2,042	1,992	2,817	3,029	2,823	2,917	2,312	2,115	2,050	2,135	0	0	0
Research and development expensed - license acquired
192	3,000	3,000	3,000	3,000	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of convertible notes payable
0	109	271	214	263	160	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of warrant liabilities
-2,203	16,501	16,132	16,547	18,050	0	58	354	-362	646	-1,828	-2,750	-3,671	-7,479	-6,495	-7,062	-6,172	-3,236	-1,804	-611	136	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Loss on warrant issuance
0	5,020	5,020	5,020	5,020	0	0	0	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on contract settlement
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	900	910	1,444	1,444	534	0	0	0	-	-	-	-	-	-	-	-
Recovery on loss on sale of subsidiary
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	50	125	200	305	255	0	0	0	-	-	-	-	-	-	-	-
Derivative liability revaluation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-517	-486	-523	-750	274	0	0	0	-	-	-	-	-	-	-	-
Loss on debt extinguishment
-	-	-	-	-	-	-	-	-	-422	-422	-422	-422	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash interest expense
-	-	-	-	-	-	-	-	-	56	136	224	320	362	340	367	307	267	244	151	162	163	186	208	241	250	0	0	0	-	-	-	-	-	-	-	-
Interest on contingent consideration
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	242	0	0	0	-	-	-	0	-	-	-	-
Other
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-114	-51	-135	-131	0	0	0	-	-	-	-	-	-	-	-
Changes in operating assets and liabilities from continuing operations:
(Gain)/loss on disposal/sale of fixed assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Accounts receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-159	-253	616	445	620	793	-633	-127	-253	-3,449	-668	-1,669	-682	2,383	310	600	-90	0	0	0
Inventories
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	194	-179	34	-147	-61	-12	133	369	341	0	0	0	-	-	-	-	-	-	-	-
Decrease (increase) in other receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Prepaid expenses and other current assets
431	686	780	524	909	6	161	-61	80	84	-112	-45	-167	-408	-509	-136	6	466	584	375	584	464	392	343	-72	-143	65	467	870	928	965	581	112	54	0	0	0
Other assets
-	-	-	-	-	-	-	-11	-29	-25	-47	-32	160	-40	-17	-18	-186	13	0	0	0	-	-	-	-	52	0	0	0	-	-	-	0	-	-	-	0
Other assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable
861	-1,424	23	-28	1,480	1,672	998	347	-110	-705	-485	-903	-208	45	1,157	1,452	728	609	-804	-710	-201	-66	607	-332	-459	-920	-830	811	799	681	1,219	408	-58	989	0	0	0
Deferred revenue - short-term
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-
Accrued expenses
-940	1,533	591	2,848	2,022	-96	-268	-322	-1,233	-681	-820	-1,305	-690	-1,340	-693	235	-1,908	-1,276	1,018	739	3,129	2,465	-315	-1,290	-662	-476	-2,310	-272	-1,420	-1,348	723	-895	1,196	1,228	0	0	0
Accrued interest
1	13	30	97	124	131	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Licenses payable
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred offering costs
-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued compensation
-	-	-	-	-	-	-	-	-	249	12	66	333	-360	26	-80	104	111	26	162	66	160	484	313	-721	-140	244	-433	1,366	967	0	0	0	-	-	-	-
Deferred revenue - long-term
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-
Increase (decrease) in payroll related liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Deferred compensation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	0	-	0	0	0
Deferred revenue
-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-1,088	-2,277	-1,843	-5,273	-574	0	0	0	-	-	-	-	-490	356	484	317	124	0	0	0
Other liabilities
-	-	-	-	-	-	-	-	-	-7	-158	-157	-153	-121	24	-25	-74	-154	-217	-217	-215	-214	-598	-521	-308	-257	7	32	-57	-3	0	0	0	-	-	-	-
Net cash used in operating activities
-17,788	-19,305	-14,584	-12,218	-9,213	-1,581	-3,682	-6,360	-9,687	-10,571	-10,672	-9,759	-9,907	-13,780	0	0	0	-	-	-	-	-	-	-	-	-15,103	-17,957	-16,447	-13,948	-12,397	0	0	0	-	-	-	-
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-22,642	0	0	0	-	-	-	0	-	-	-	-	-	-	-	-	-	0	0	0
Purchase of fixed assets, net
-	-	-	-	-	-	-	-	-	-	-	-	-	18	139	167	178	337	296	336	390	580	954	889	891	573	532	532	453	436	87	106	275	263	0	0	0
Proceeds from sale of subsidiary
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	50	125	200	305	255	0	0	0	-	-	-	-	-	-	-	-
Proceeds from the sale of property and equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,657	0	0	0	-	-	-	-	-	-	-	-
Release of restricted cash
-	-	-	-	-	-	-	-	-	-	-	-	-	280	280	280	100	10	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by investing activities from continuing operations
-	-	-	-	-	-	-	-	-	-	-	-	-	265	0	0	0	-	-	-	-	-	-	-	-	3,059	2,136	4,752	4,717	1,368	0	0	0	-	-	-	-
Net cash provided by (used in) investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-322	0	0	0	-	-	-	0	-	-	-	-	-	-	-	-	-	0	0	0
Cash flows from financing activities:
Proceeds from issuance of common stock and warrants in a private offering
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of common stock, pursuant to Securities Purchase Agreement, net of issuance costs
25,370	16,520	15,255	15,955	-65	0	0	0	0	-	-	-	-	14,762	14,785	9,605	9,859	10,869	11,764	14,606	15,229	5,913	5,018	2,176	17,462	16,612	17,533	17,533	1,712	20,410	20,410	22,904	23,209	6,157	0	0	0
Proceeds from exercise of warrants
1,847	4,517	4,443	4,443	2,670	0	289	289	289	289	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	40	62	80	503	1,364	0	0	0
Repayment of notes payable
-	-	-	-	-	-	-	-	-	7,129	7,931	8,716	9,487	3,113	2,806	2,021	1,250	495	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from the exercise of stock options
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	83	83	83	83	0	0	0	0	-	-	-	-	10	0	0	0	-	-	-	-
Net cash provided by financing activities
19,184	29,524	29,560	21,763	20,490	1,365	0	0	0	-	-	-	-	-	-	-	-	15,451	0	0	0	-	-	-	0	-	-	-	-	-	-	-	-	-	0	0	0
Release (deposit) of restricted cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-
Repayment of short-term borrowing
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Repayment of capital lease obligations
-	-	-	-	-	-	-	-	-	-	-	-	-	5	6	6	5	6	7	13	21	27	17	19	35	27	0	0	0	-	-	-	-	20	0	0	0
Deposit of restricted cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	553	0	0	0
Net cash provided by financing activities from continuing operations
-	-	-	-	-	-	-	-	-	-	-	1,876	-5,317	11,003	0	0	0	-	-	-	-	-	-	-	-	16,631	17,853	17,867	2,023	20,766	0	0	0	-	-	-	-
Cash flows from discontinued operations:
Net cash (used in) provided by operating activities of discontinued operations
-	-	-	-	-	-	-	-	-	105	-26	1,228	408	712	0	0	0	-	-	-	-	-	-	-	-	38	-850	-1,051	-2,046	-1,985	0	0	0	-	-	-	-
Net cash provided by investing activities of discontinued operations
-	-	-	-	-	-	-	-	-	-	-	11,750	11,500	0	0	0	0	-	-	-	-	-	-	-	-	1,650	2,460	1,460	1,460	-300	0	0	0	-	-	-	-
Net cash provided by (used in) discontinued operations
-	-	-	-	-	-	-	-	-	12,314	11,974	12,978	11,908	712	0	0	0	-	-	-	-	-	-	-	-	1,688	1,610	409	-586	-2,285	0	0	0	-	-	-	-
Effect of exchange rate changes on cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Net increase in cash
1,396	10,219	14,976	9,545	11,277	-216	-2,051	-1,565	2,326	4,244	2,849	5,098	-3,145	-1,800	-195	-4,710	-9,249	-7,513	-10,300	-9,987	-6,335	-10,005	-4,510	-7,344	8,387	6,275	3,758	6,824	-7,425	7,695	7,982	8,799	11,353	-1,711	0	0	0
Supplemental disclosure of cash flow information:
Cash paid for interest
-	-	-	-	-	-	-	-	-	-	-	384	553	646	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	318	381	232	321	333	0	0	0
Cash paid for interest
15	16	16	11	5	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for income taxes
0	0	0	0	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash investing and financing activities:
Issuance of common stock for conversion of debt and accrued interest
0	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Issuance of common stock for conversion of accrued interest
0	164	164	164	164	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Effect of reverse merger
0	299	299	299	299	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Reclass of warrant liabilities related to Series A warrants exercised for cash
1,944	5,600	5,504	5,504	3,656	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Reclass of Series B warrants from warrant liability to stockholders' equity
0	31,473	31,473	31,473	31,473	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Transaction costs for 2018 financing activities
-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Transaction costs for 2016 financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Capital lease payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of fixed assets not yet paid
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Liabilities incurred in connection with the purchase of fixed assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Accrued transaction costs for 2016 financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Issuance of placement agent warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Reclassification of warrant liabilities to equity
-	-	-	-	-	-	-	-	-	798	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Issuance of restricted stock
-	-	-	-	-	-	-	-	-	-	-	-	-	249	249	249	249	0	0	0	0	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Accrued transaction costs for financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-